Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of LYN polyclonal antibody
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Goat |
| Applications | ELISA,WB-Ce |
More info about LYN polyclonal antibody
| Brand: | Abnova |
| Reference: | PAB7459 |
| Product name: | LYN polyclonal antibody |
| Product description: | Goat polyclonal antibody raised against synthetic peptide of LYN. |
| Gene id: | 4067 |
| Gene name: | LYN |
| Gene alias: | FLJ26625|JTK8 |
| Gene description: | v-yes-1 Yamaguchi sarcoma viral related oncogene homolog |
| Immunogen: | A synthetic peptide corresponding to human LYN. |
| Immunogen sequence/protein sequence: | C-KTQPVRNTERT |
| Protein accession: | NP_002341.1 |
| Form: | Liquid |
| Concentration: | 0.5 mg/mL |
| Recommend dilutions: | ELISA (1:16000) Western Blot (0.1-0.3 ug/mL) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In Tris saline, pH 7.3 (0.5% BSA, 0.02% sodium azide) |
| Storage instruction: | Store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Goat |
| Antigen species / target species: | Human |
| Reactivity: | Human |
| Application image: |  |
| Application image note: | LYN polyclonal antibody (Cat # PAB7459) (0.1 ug/mL) staining of U-937 lysate (35 ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. |
| Applications: | ELISA,WB-Ce |
| Shipping condition: | Dry Ice |
| Publications: | Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T. Leukemia. 2007 Mar;21(3):403-10. Epub 2007 Jan 18. |